MeSH tree: E05.478.550.520.050.400
Metabolic tumor volume—a biomarker derived from PET imaging—can more accurately predict progression-free survival for large B-cell lymphoma patients than the widely used International Prognostic Index. By identifying patients ...
Apr 22, 2026
0
1
A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II ...
Apr 20, 2026
0
4
For the first time, scientists have used a modern cell therapy called CAR-T to treat a patient with three different life-threatening autoimmune diseases that had resisted years of treatment. The patient, who once required ...
Apr 9, 2026
0
23
A technique that transforms immune cells into cancer-seeking bloodhounds may overcome a roadblock that has hampered immunotherapy for solid tumors, according to a new study by Stanford Medicine researchers. The approach equips ...
Mar 24, 2026
0
17
Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial dysfunction has been recognized as a hallmark of exhausted T cells in tumors. Yet how metabolic stress ...
Mar 18, 2026
0
11
Lymph nodes, considered the command centers of our immune system, often get swollen and stiff when fighting infection. Now, a UC Berkeley-led team of researchers has discovered that this mechanical change may help instruct ...
Mar 12, 2026
0
8
A new study has revealed a promising new approach to curb the spread of triple-negative breast cancer, one of the most aggressive and difficult-to-treat forms of the disease. Published recently in Cancer Letters, Gabriel ...
Mar 10, 2026
0
19
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T cells to target specific ...
Mar 9, 2026
0
9
CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone lymphoma, according to a recent clinical trial published in The Lancet. Marginal zone lymphoma ...
Mar 4, 2026
0
6
UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block their attack, and fuel ...
Mar 4, 2026
0
13
